Alnylam Pharmaceuticals, Inc. (ALNY)
Largest Insider Buys in Sector
ALNY Stock Price History Chart
ALNY Stock Performance
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; …
Insider Activity of Alnylam Pharmaceuticals, Inc.
Over the last 12 months, insiders at Alnylam Pharmaceuticals, Inc. have bought $0 and sold $54.85M worth of Alnylam Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Alnylam Pharmaceuticals, Inc. have bought $0 and sold $44.8M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 595,002 shares for transaction amount of $42.76M was made by Sanofi (10 percent owner) on 2017‑05‑31.
List of Insider Buy and Sell Transactions, Alnylam Pharmaceuticals, Inc.
| 2024-12-12 | Sale | CMO & EVP Dev & Med Affairs | 1,752 0.0014% | $251.00 | $439,760 | +0.07% | ||
| 2024-11-27 | Sale | CSO & EVP, Head of Research | 1,531 0.0012% | $252.29 | $386,261 | -0.52% | ||
| 2024-11-26 | Sale | Chief Executive Officer | 5,219 0.004% | $250.98 | $1.31M | -0.13% | ||
| 2024-11-26 | Sale | EVP, Chief Financial Officer | 1,682 0.0013% | $250.98 | $422,144 | -0.13% | ||
| 2024-11-26 | Sale | CMO & EVP Dev & Med Affairs | 1,682 0.0013% | $250.98 | $422,144 | -0.13% | ||
| 2024-11-26 | Sale | CSO & EVP, Head of Research | 1,469 0.0011% | $250.98 | $368,686 | -0.13% | ||
| 2024-11-26 | Sale | EVP, Chief Commercial Officer | 1,469 0.0011% | $250.98 | $368,686 | -0.13% | ||
| 2024-08-20 | Sale | Chief Executive Officer | 15,000 0.0117% | $280.00 | $4.2M | -4.14% | ||
| 2024-08-12 | Sale | CSO & EVP, Head of Research | 22,025 0.0172% | $270.99 | $5.97M | -0.24% | ||
| 2024-08-06 | Sale | director | 20,250 0.0157% | $262.00 | $5.31M | +2.65% | ||
| 2024-08-01 | Sale | Chief Executive Officer | 15,148 0.012% | $270.00 | $4.09M | +0.34% | ||
| 2024-07-11 | Sale | Chief Executive Officer | 7,093 0.006% | $261.00 | $1.85M | 0.00% | ||
| 2024-06-25 | Sale | Chief Executive Officer | 8,301 0.0063% | $230.99 | $1.92M | +11.34% | ||
| 2024-06-25 | Sale | EVP, Chief Financial Officer | 1,605 0.0012% | $231.00 | $370,747 | +11.34% | ||
| 2024-06-25 | Sale | CMO & EVP Dev & Med Affairs | 2,103 0.0016% | $230.99 | $485,773 | +11.34% | ||
| 2024-06-25 | Sale | CSO & EVP, Head of Research | 1,198 0.0009% | $230.99 | $276,731 | +11.34% | ||
| 2024-06-25 | Sale | EVP, Chief Commercial Officer | 1,605 0.0012% | $231.00 | $370,747 | +11.34% | ||
| 2024-06-25 | Sale | director | 8,500 0.0067% | $240.00 | $2.04M | +11.34% | ||
| 2024-06-24 | Sale | director | 32,450 0.0254% | $220.69 | $7.16M | +19.68% | ||
| 2024-05-29 | Sale | director | 21,700 0.0173% | $148.60 | $3.22M | +75.69% |
Insider Historical Profitability
| BONNEY MICHAEL W | director | 16029 0.0124% | $245.44 | 2 | 2 | <0.0001% |
| PYOTT DAVID E I | director | 136 0.0001% | $245.44 | 1 | 1 | +45.98% |
| SHARP PHILLIP A | director | 0 0% | $245.44 | 2 | 14 | +68.46% |
| Sanofi | 10 percent owner | 10554134 8.1827% | $245.44 | 6 | 0 | +18.68% |
| NOVARTIS AG | 10 percent owner | 4051002 3.1408% | $245.44 | 3 | 1 | <0.0001% |
Institutional Investor Ownership
| Capital World Investors | $1.91B | 10.11 | 12.79M | -20.93% | -$505.94M | 0.32 | |
| The Vanguard Group | $1.79B | 9.48 | 11.99M | +0.42% | +$7.53M | 0.03 | |
| Fidelity Investments | $1.49B | 7.88 | 9.97M | -3.34% | -$51.46M | 0.1 | |
| BlackRock | $1.35B | 7.14 | 9.03M | +5.91% | +$75.31M | 0.03 | |
| Wellington Management Company | $1.08B | 5.7 | 7.21M | -0.07% | -$776,093.85 | 0.18 |